p53: State-of-the-Art in Revealing Cancer Targets
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Nuclei: Function, Transport and Receptors".
Deadline for manuscript submissions: 25 June 2024 | Viewed by 198
Special Issue Editors
Interests: cellular senescence; cancer; p53-MDM2 complex; probiotic; mycotoxins
Special Issue Information
Dear Colleagues,
It is an honor to announce the launch of a Special Issue on the role of ‘p53’: State-of-the-Art in Revealing Cancer Targets. The protein p53 is a tumor suppressor, which is also called the guardian of the genome. The protein was initially discovered in the year 1979, and well characterized as an oncogene until it was found to be frequently mutated in cancer. This tumor suppressor protein is encoded by TP53 gene. The TP53 expression level has been used for better prognostic markers, predictors of outcome and chemotherapy response in cancer patients, than that of patients expressing mutated TP53. The p53 protein not only plays a critical role for preserving genome integrity, but it also plays other roles aside from keeping the genome safe, like it is also involved in apoptosis and autophagy cross-talk. p53 is required to suppress tumorigenesis, but also elicits detrimental effects when aberrantly overexpressed. There are several molecular mechanisms involved which modulate p53 level and function. For example, overexpression of MDM2 protein, p53 isoform expression, and RNA-binding proteins are also involved, which regulates p53 expression, activity, and function. The scope of this special issue is to describe the cutting-edge novel findings for a better understanding of its role, function and its interaction with other partner proteins. This topic also welcomes the identification of novel strategies and molecules to activate p53 protein or reactivated mutated p53 protein to contribute to the improvement of current ongoing cancer therapeutics.
Dr. Debasish Kumar Dey
Dr. Anoop Kumar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mutant TP53
- alternative splicing of p53, small p53 activators
- post-translational modification
- p53 interaction with partner protein
- apoptosis and autophagy cross-talk
- tumor microenvironment
- immunotherapy
